Description: This seminar is designed to give life and annuity practitioners an in-depth view of the important topics and fundamentals of reinsurance, from the perspective of a U.S. life insurance company. Reinsurance industry experts will present on the various types of reinsurance, contract issues, financial implications and other considerations. Attendees will leave this seminar with a stronger understanding of life and annuity reinsurance, and current topics. Keep in mind this seminar is designed for participants with a moderate level of experience. Educational Objectives • Provide attendees with a stronger understanding of life and annuity reinsurance, and current topics • Give attendees an in-depth view of important topics and fundamentals of reinsurance

Description: This session will look into life insurers’ anticipated business impacts as a result of the implementation of the new accounting standard for insurance contracts, IFRS 17. What will be the financial impact as of day one as a result of transition? How will embedded value for common life insurance products change? How will costs of reinsurance be affected? Will products have to be re-designed and/or re-priced? IFRS 17 may have more ramifications into the way insurers are doing business than we have anticipated so far. While we are working on the implementation of this new standard, we should not lose sight of the business impacts that will follow. At the conclusion of the session, attendees will be able to: Understand key impacts of the transition to IFRS 17; See illustrative examples of the impact on embedded value; and Understand key impacts on product design and pricing Country Relevance: US and Canada

Description: The reinsurance market is experiencing unprecedented growth in both frequency and severity of catastrophic medical claims. Most experts identify specialty drugs, new gene therapies and high-intensity hospital in-patient stays as contributing factors. With Rx claims, high-cost drug protocols are creating chronic high-cost cases over multiple years. What can actuaries do to rapidly identify these cases? If identified, what techniques can be used to reduce or manage cost? Panel will include a nationally recognized consulting actuary, health plan executive and reinsurance executive.